Covidien to Host Investor Meeting on September 13, 2012

Covidien to Host Investor Meeting on September 13, 2012

<0> Covidien plcEric Kraus, 508-261-8305Senior Vice PresidentCorporate CommunicationsorColeman Lannum, CFA, 508-452-4343Vice PresidentInvestor RelationsorBruce Farmer, 508-452-4372Vice PresidentPublic RelationsorTodd Carpenter, 508-452-4363DirectorInvestor Relations </0>

(NYSE: COV), a leading global provider of healthcare products, will host an investor meeting on Thursday, September 13, 2012, to update the investment community on the Company and its growth initiatives, strategic priorities and financial outlook. The event, held at Cipriani, 55 Wall Street, New York, NY, will begin around noon and is expected to conclude by 5:00 p.m.

The program will include presentations by Covidien's Chairman, President and CEO José (Joe) Almeida and other members of the senior management team. A more detailed agenda will be communicated prior to the meeting.

Advanced registration is required and attendance will be limited to those who register in advance. To register for the meeting, please go to the following website:

Individuals who are unable to attend the meeting in person will be able to view a live video and webcast at Covidien’s website: . A replay of the presentations and the presentation materials will be available at the same website following the conclusion of the meeting.

Covidien is a leading global healthcare products company that creates innovative medical solutions for better patient outcomes and delivers value through clinical leadership and excellence. Covidien manufactures, distributes and services a diverse range of industry-leading product lines in three segments: Medical Devices, Pharmaceuticals and Medical Supplies. With 2011 revenue of $11.6 billion, Covidien has 43,000 employees worldwide in more than 65 countries, and its products are sold in over 140 countries. Please visit to learn more about our business.

Suggested Articles

Loretta Itri, M.D. has been helping Immunomedics out with its troubled antibody-drug conjugate. Now, she’s signing on as its chief medical officer.

Light Chain Bioscience, a unit of Swiss biotech Novimmune, has been handed a nice royalty milestone check from partner Takeda.

The fund received money from Chinese organizations inside and outside the biopharma industry, enabling CICC Capital to ease past its financing goal.